---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-040100"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:04:48.045155+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ensysce Q3 net loss narrows to $2.7M; cash $1.5M; PF614 study results expected by year-end

## Summary
- Net loss attributable to common stockholders was $2.7M ($0.87/share) vs $9.9M ($61.58) in Q3 2022.
- Cash and cash equivalents $1.5M as of Sep 30, 2023, down from $3.8M at June 30; post-quarter raised $1.7M in convertible notes.
- R&D expenses fell to $1.9M from $4.8M; G&A expenses fell to $1.2M from $1.7M.
- PF614-201 time-of-onset study results expected in December 2023; FDA End of Phase 2 meeting set for Jan 30, 2024.

## SEC filing metadata
- accession: 0001493152-23-040100
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315223040100/0001493152-23-040100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315223040100/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-040100
- JSON: https://secwatch.observer/filing/0001493152-23-040100.json
- Plain text: https://secwatch.observer/filing/0001493152-23-040100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.